Regular ArticleDose of BCG does not influence the efficient generation of protective immunity in mice challenged with Mycobacterium tuberculosis
References (21)
- et al.
Assessment of worldwide tuberculosis control. WHO Global Surveillance and Monitoring Project
Lancet
(1997) - et al.
How environmental mycobacteria may predetermine the protective efficacy of BCG
Tubercle
(1981) Comparative genomics of BCG vaccines
Tuberculosis
(2001)A strategy to improve the efficacy of vaccination against tuberculosis and leprosy
Immunol Today
(1992)Prospects for low dose BCG vaccination against tuberculosis
Immunobiology
(1994)- et al.
The progression of chronic tuberculosis in the mouse does not require the participation of B lymphocytes or interleukin-4
Exp Gerontol
(2001) - et al.
Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project
JAMA
(1999) The global problem of multidrug-resistant tuberculosis: the genie is out of the bottle
JAMA
(2000)- et al.
Risk of Mycobacterium tuberculosis transmission in a low-incidence country due to immigration from high-incidence areas
J Clin Microbiol
(2001) - et al.
Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature
JAMA
(1994)
Cited by (27)
Evidence for enhanced central memory priming by live Mycobacterium bovis BCG vaccine in comparison with killed BCG formulations
2008, VaccineCitation Excerpt :Reducing the dose of BCG can promote a Th1 biased response [37], a manifestation of CMI commonly associated with enhanced control of TB [31]. Whilst this might be suggestive of lower doses of BCG being be more protective, when tested empirically, vaccination of mice with various doses of BCG ranging from 103 to 107 CFU did not influence efficient generation of protective immunity against M. tuberculosis challenge [38]. A mechanism proposed to explain the poor protective efficacy commonly associated with killed mycobacterial vaccines is that immuno-dominant protective antigens are only generated by live actively metabolising bacilli [17].
The safety and immunogenicity of Bacillus Calmette-Guérin (BCG) vaccine in European badgers (Meles meles)
2006, Veterinary Immunology and Immunopathology
- f1
Correspondence to: Veronica Gruppo, Mycobacteria Research laboratories, Department of Microbiology, Immunology, and Pathology, Colorado State University, Fort Collins CO 80523, USA. Tel.: +1-970-491-6587; Fax: +1-970-491-5125; e-mail: [email protected]